Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Schizophrenia in microcephalic osteodysplastic primordial dwarfism type II syndrome: supporting evidence for an association between the PCNT gene and schizophrenia.

Ozel F, Direk N, Ataseven Kulali M, Giray Bozkaya O, Ada E, Alptekin K.

Psychiatr Genet. 2018 Dec 6. doi: 10.1097/YPG.0000000000000214. [Epub ahead of print]

PMID:
30531648
2.

Functional coupling between adenosine A1 receptors and G-proteins in rat and postmortem human brain membranes determined with conventional guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding or [35S]GTPγS/immunoprecipitation assay.

Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Matsuoka I, García-Sevilla JA.

Purinergic Signal. 2018 Jun;14(2):177-190. doi: 10.1007/s11302-018-9603-x. Epub 2018 Feb 28.

3.

Cell-subtype-specific changes in adenosine pathways in schizophrenia.

O'Donovan SM, Sullivan C, Koene R, Devine E, Hasselfeld K, Moody CL, McCullumsmith RE.

Neuropsychopharmacology. 2018 Jul;43(8):1667-1674. doi: 10.1038/s41386-018-0028-6. Epub 2018 Feb 26.

PMID:
29483661
4.

Adaptive combination of Bayes factors as a powerful method for the joint analysis of rare and common variants.

Lin WY, Chen WJ, Liu CM, Hwu HG, McCarroll SA, Glatt SJ, Tsuang MT.

Sci Rep. 2017 Oct 24;7(1):13858. doi: 10.1038/s41598-017-13177-7.

5.

Elevated serum adenosine deaminase levels in neuroleptic-naïve patients with recent-onset schizophrenia.

Sasidharan A, Kumar S, John JP, Philip M, Subramanian S, Jain S, Kutty BM.

Asian J Psychiatr. 2017 Oct;29:13-15. doi: 10.1016/j.ajp.2017.03.034. Epub 2017 Mar 27.

PMID:
29061410
6.

Investigation into effects of antipsychotics on ectonucleotidase and adenosine deaminase in zebrafish brain.

Seibt KJ, Oliveira Rda L, Bogo MR, Senger MR, Bonan CD.

Fish Physiol Biochem. 2015 Dec;41(6):1383-92. doi: 10.1007/s10695-015-0093-2. Epub 2015 Jul 9.

PMID:
26156500
7.

Paliperidone regulates intracellular redox system in rat brain: Role of purine mechanism.

Demirci K, Özçankaya R, Yilmaz HR, Yiğit A, Uğuz AC, Karakuş K, Demirdaş A, Akpınar A.

Redox Rep. 2015 Jul;20(4):170-6. doi: 10.1179/1351000214Y.0000000122. Epub 2014 Dec 29.

PMID:
25545018
8.

Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia.

Saddichha S, Vishnuvardhan G, Akhtar S.

Int J Risk Saf Med. 2011;23(3):181-5. doi: 10.3233/JRS-2011-0536.

PMID:
22020398
9.

Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial.

Ghaleiha A, Honarbakhsh N, Boroumand MA, Jafarinia M, Tabrizi M, Rezaei F, Raznahan M, Akhondzadeh S.

Hum Psychopharmacol. 2011 Mar;26(2):120-4. doi: 10.1002/hup.1176. Epub 2011 Mar 16.

PMID:
21412846
10.

Lower frequency of the low activity adenosine deaminase allelic variant (ADA1*2) in schizophrenic patients.

Dutra GP, Ottoni GL, Lara DR, Bogo MR.

Braz J Psychiatry. 2010 Sep;32(3):275-8. Epub 2010 Apr 23.

11.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
12.

Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.

Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW.

Am J Psychiatry. 2009 Mar;166(3):345-53. doi: 10.1176/appi.ajp.2008.08030383. Epub 2009 Jan 15.

PMID:
19147694
13.

[Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics].

Cordes J, Sinha-Röder A, Kahl KG, Malevani J, Thuenker J, Lange-Asschenfeldt C, Hauner H, Agelink MW, Klimke A.

Fortschr Neurol Psychiatr. 2008 Dec;76(12):703-14. doi: 10.1055/s-2008-1038279. Epub 2008 Oct 15. Review. German.

PMID:
18924059
14.

The role of atypical antipsychotic agents in the treatment of schizophrenia and schizoaffective disorders in the elderly.

Madhusoodanan S, Sinha A, Sajatovic M, Gupta S, Brenner R.

Curr Drug Saf. 2006 Aug;1(3):227-41. Review.

PMID:
18690933
15.

[Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics].

De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J.

Encephale. 2007 Mar-Apr;33(2):197-202. French.

PMID:
17675915
16.

Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods.

van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J.

J Clin Psychiatry. 2006 Oct;67(10):1493-500.

PMID:
17107239
17.

Metabolic issues and cardiovascular disease in patients with psychiatric disorders.

Casey DE.

Am J Med. 2005 Apr;118 Suppl 2:15S-22S. Review.

PMID:
15903291
18.
19.

Psychosocial assessment of organ transplant candidates and the Americans with Disabilities Act.

Orentlicher D.

Gen Hosp Psychiatry. 1996 Nov;18(6 Suppl):5S-12S. Review.

PMID:
8937917

Supplemental Content

Loading ...
Support Center